Investment Thesis
Coeptis Therapeutics is a pre-revenue biotech company with severe operational losses and negative cash burn that is unsustainable at current run rates. The company generated only $1.4M in revenue while burning $8.6M in operating cash flow, resulting in a -631% free cash flow margin with minimal runway based on $5.7M cash reserves. Despite strong balance sheet liquidity metrics, the company exhibits classic characteristics of a failing biotech venture with deteriorating fundamentals and no clear path to profitability.
Strengths
- Strong current ratio of 4.16x indicates short-term liquidity to meet immediate obligations
- Minimal debt burden with 0.01x debt-to-equity ratio providing financial flexibility
- High gross margin of 86.7% suggests strong unit economics if revenue scales, typical of biotech
- 9 Form 4 filings in last 90 days indicate insider engagement and activity
Risks
- Extreme cash burn of $8.6M annually against only $1.4M revenue is unsustainable; ~8 months of cash runway remaining
- Operating margin of -956.9% and net margin of -874.3% indicate massive losses with no near-term profitability path
- Minimal revenue generation suggests failed commercialization, late-stage development issues, or loss of market traction
- Negative ROE of -87.9% and ROA of -73.8% demonstrate value destruction for shareholders
- Pre-revenue biotech status with no clear pipeline success or upcoming catalyst visible in fundamentals
Key Metrics to Watch
- Operating cash flow trend and months of cash runway remaining
- Revenue growth trajectory and pipeline advancement milestones
- Quarterly cash burn rate changes and capital efficiency improvements
- Clinical trial progress and FDA approval status for key programs
- Working capital management and potential dilutive financing needs
Financial Metrics
Revenue
1.4M
Net Income
-11.9M
EPS (Diluted)
$-2.81
Free Cash Flow
-8.6M
Total Assets
16.2M
Cash
5.7M
Profitability Ratios
Gross Margin
86.7%
Operating Margin
-956.9%
Net Margin
-874.3%
ROE
-87.9%
ROA
-73.8%
FCF Margin
-631.2%
Balance Sheet & Liquidity
Current Ratio
4.16x
Quick Ratio
4.16x
Debt/Equity
0.01x
Debt/Assets
12.9%
Interest Coverage
-48.93x
Long-term Debt
150.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T18:48:20.219489 |
Data as of: 2025-12-31 |
Powered by Claude AI